BridgeBio Oncology Therapeutics, Inc.
BBOTNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $236.16K
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.88$14.87
- Volume (live)
- -
- Avg. volume (3M)
- 707.11K
BridgeBio Oncology Therapeutics (BBOT) Stock Price & Financial Analysis
BridgeBio Oncology Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.81 - $2.95 |
|---|---|
| 52-Week High | $14.87 |
| 52-Week Low | $2.88 |
| Open | $2.95 |
| Volume (last close) | 480.76K |
| Average Volume (3M) | 707.11K |
| 50-Day MA | $6.54 |
|---|---|
| 200-Day MA | $8.71 |
| 1-Year Change | −73.54% |
| Market Cap | 236.16K |
|---|---|
| Shares Outstanding | 80.05K |
| Price to Book (P/B) | 0.00 |
| EV/EBITDA | 0.26 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
BridgeBio Oncology Therapeutics at a Glance
As of the Oct 16, 2026 close, BridgeBio Oncology Therapeutics (BBOT) has a market capitalization of $236.16K.
As of its latest reported balance sheet, it holds $54.06M in cash and securities against $2.51M of debt, a net cash position of $51.55M.
BridgeBio Oncology Therapeutics does not currently pay a dividend.
The share price is down 73.5% over the past year. At $2.82 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $2.88 to $14.87, below its 200-day moving average of $8.71.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $21.00, 644.7% above the Oct 16, 2026 close.
Frequently Asked Questions About BridgeBio Oncology Therapeutics
What is the current stock price for BBOT?
As of the Oct 16, 2026 close, BBOT stock trades at $2.82. The 52-week range is $2.88–$14.87, with a day range of $2.81–$2.95.
What is the P/E ratio for BBOT?
The P/E ratio (Price-to-Earnings) for BBOT is shown in the Key Statistics section. This valuation metric helps compare BridgeBio Oncology Therapeutics, Inc. to industry peers.
Does BBOT pay dividends?
BridgeBio Oncology Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BBOT?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for BBOT is Buy. The average 12-month price target is $21.00, a 644.7% upside from the Oct 16, 2026 close of $2.82.
What is the market cap of BBOT?
As of the Oct 16, 2026 close, BridgeBio Oncology Therapeutics's market capitalization is $225,752.28, classifying it as a micro-cap company. BridgeBio Oncology Therapeutics operates in the Healthcare sector within the Biotechnology industry.